ClinicalTrials.gg
WithdrawnNCT03538392Updated Apr 10, 2020

Serranator® Alto Post Market Clinical Follow Up (PMCF) Study

An observational study in Peripheral Arterial Disease, Arterio-venous Fistula and Arteriovenous Graft, sponsored by Cagent Vascular LLC. Withdrawn. Per ClinicalTrials.gov, last updated 2020-04-10.

Sponsored by Cagent Vascular LLC · Observational

How we know

Why this study was withdrawn
Product not available, study withdrawn

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Sex
All
01

Study summary

The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® Alto in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario.

Read the detailed description

Single Arm, multi-center, device registry study capturing de-identified data on a minimum of 100 subjects with peripheral artery disease (PAD) and/or dysfunctional native or synthetic arteriovenous dialysis fistulae. The study will capture acute angiographic data.

02

Conditions studied

  • Peripheral Arterial Disease
  • Arterio-venous Fistula
  • Arteriovenous Graft
03

In context

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Cagent Vascular LLC is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of subjects with claudication or ischemic rest pain, requiring dilatation of lesions, in the iliac or femoropopliteal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistulae.

Eligibility criteria

  • Subject requires angioplasty
  • Subject has a lesion in the iliac, femoral, iliofemoral, popliteal artery, or obstructive lesion of native or synthetic arteriovenous dialysis fistulae as per the product indications for use
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • PAD

    Device: Serranator® Alto

  • AV Fistula

    Device: Serranator® Alto

  • AV Graft

    Device: Serranator® Alto

Interventions

  • DeviceSerranator® Alto

    Serranator® Alto PTA Serration Balloon Catheter

06

What researchers measure

Primary outcomes

  1. Performance

    Device Success defined as the achievement of successful delivery, balloon inflation and deflation, and retrieval of the study device(s) with a diameter stenosis of \<50% by visual assessment at the intended target site after using the Serranator® device.

    Time frame: The registry will collect acute procedural data through hospital discharge, no additional follow up is required. Performance data will be summarized after enrollment is complete, estimated to be 1 year.

Secondary outcomes

  1. Collection of device related Major Adverse Events (MAE) until discharge

    Safety defined as incidence of device related MAE, defined as amputations or re-interventions (surgical or endovascular)

    Time frame: Within 12-24 hours post-procedure or prior to hospital discharge, whichever occurs first

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2019; primary completion for Dec 2019, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2018
First posted
May 29, 2018
StartEst.
Sep 2019
Primary completionEst.
Dec 2019
CompletionEst.
Dec 2019
Last update
Apr 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03538392
Lead sponsor
Cagent Vascular LLC
Responsible party
Sponsor
First posted
May 29, 2018
Start date
Sep 2019 (estimated)
Primary completion
Dec 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Apr 10, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion